This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Edward Owens, Ironwood Board Of Directors (Photo: Business Wire)

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment of Edward Owens to its board of directors. Mr. Owens is a recently retired partner, portfolio manager and global industry analyst with Wellington Management Company, LLP.
Edward Owens, Ironwood Board of Directors (Photo: Business Wire)

Edward Owens, Ironwood Board of Directors (Photo: Business Wire)

“Ed has gained a unique perspective on how to optimally allocate capital, create value for shareholders and build and run successful businesses based on nearly four decades of outstanding performance investing in healthcare companies,” said Peter Hecht, chief executive officer of Ironwood. “He has deeply probed the strategy, growth, successes and challenges of nearly every company in the healthcare space during his investing career, and we are thrilled to have the opportunity to tap into his insights, business savvy and ownership focus.”

“I’ve closely followed Ironwood for eight years and have been a shareholder since their IPO in 2010. During that time, I have had the opportunity to gain a deep appreciation for Ironwood’s business acumen and long-term vision,” said Mr. Owens. “I have been very impressed with the competence, entrepreneurial spirit and high ethical standards of the management team. After decades of observing companies from the outside, I am excited to be part of what I hope and expect will be one of the next great growth companies in biotech. The execution of a successful launch of LINZESS™ (linaclotide) should provide our team with the resources to build an exceptional business, focused on improving human health and advancing patient care.”

Mr. Owens started at Wellington in 1974 and served as portfolio manager for the Vanguard Health Care Fund from its inception in May 1984 until his retirement in December 2012. During his tenure, the Vanguard Health Care Fund was the best performing mutual fund among all mutual funds. Consistently outperforming the Lipper Global Health/Biotech Funds Average and the S&P 500 Index, it grew to be by far the largest mutual fund in the global health/biotech category. Mr. Owens has a B.S. in Physics from the University of Virginia and an M.B.A. from Harvard Business School. He has been recognized numerous times for his investment performance and has been chosen twice as a finalist for Morningstar's Fund Manager of the Year.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.42 1.90%
FB $117.83 -0.62%
GOOG $696.05 -0.31%
YHOO $36.13 -1.10%
TSLA $233.51 -3.40%


Chart of I:DJI
DOW 17,762.45 -128.71 -0.72%
S&P 500 2,062.83 -18.60 -0.89%
NASDAQ 4,769.7260 -47.8680 -0.99%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs